Timing around supplements and other medications Injectable GLP-1 agonists do not have significant drug interactions related to timing because they bypass the gastrointestinal tract
GIC requests additional $240 million On the same day the BCBS news broke, the Massachusetts Group Insurance Commission met on Beacon Hill to go over a budget shortfall
Within the findings were several considerations for patients and payers: High costs for GLP-1 medications ranked as respondents top concern (followed by lack of control over who is prescribed the medications) 93% covered GLP-1s for management of diabetes in the previous plan year
Remember, youre not alone
Back DiMarchi, R Efendic, S (1997) 'Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity', US Patent US6191102B1.Back Drucker, DJ, Habener, JF, Holst, JJ (1 Dec 2017) 'Discovery, characterization, and clinical development of the glucagon-like peptides', Journal of Clinical Investigation , 127/12, 4217-27
